KIT and gastrointestinal stromal tumor: These data suggest that the over-expression of KIT may play a major role in IMA-resistance and decreasing KIT expression or inhibiting the signaling pathways that regulate KIT may lead to significant clinical benefit for GIST patients with IMA-resistance [10, 11].